EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)

Company Overview - Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, focusing on developing innovative antibody-based therapies for cancer treatment [3] Recent Developments - H.C. Wainwright has cut its price target for Genmab A/S from $41 to $39 while maintaining a Buy rating on the company's shares [1] - The price target adjustment follows the announcement that Genmab and partner AbbVie found no meaningful improvement in overall survival for EPKINLY (epcoritamab) monotherapy compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) patients [1] Future Outlook - Despite the recent trial results, H.C. Wainwright believes that EPKINLY will likely retain its 2023 accelerated clearance for third-line DLBCL treatment until the results of two additional ongoing Phase 3 trials are released [2] - The firm referenced Roche's Columvi as a precedent, which maintained its accelerated approval despite missing overall survival targets in a similar patient group while awaiting further study findings [2] Investment Considerations - While Genmab is recognized for its potential as an investment, there are opinions suggesting that certain AI stocks may offer greater upside potential and carry less downside risk [4]